Quantitative Clinical Rheumatology: "Keep It Simple, Stupid": MDHAQ Function, Pain, Global, and RAPID3 Quantitative Scores to Improve and Document the Quality of Rheumatologic Care

THEODORE PINCUS and TUULIKKI SOKKA

J Rheumatol 2009;36;1099-1100
http://www.jrheum.org/content/36/6/1099

1. Sign up for TOCs and other alerts
http://www.jrheum.org/alerts

2. Information on Subscriptions
http://jrheum.com/faq

3. Information on permissions/orders of reprints
http://jrheum.com/reprints_permissions

The Journal of Rheumatology is a monthly international serial edited by Earl D. Silverman featuring research articles on clinical subjects from scientists working in rheumatology and related fields.
Quantitative Clinical Rheumatology: “Keep It Simple, Stupid”: MDHAQ Function, Pain, Global, and RAPID3 Quantitative Scores to Improve and Document the Quality of Rheumatologic Care

“The KISS principle (acronym for “Keep It Simple, Stupid”) states that design simplicity should be a key goal and unnecessary complexity avoided.... Extra features are not needed; an approach that seems “too easy to be true” is in fact the best way.”

— Wikipedia (http://en.wikipedia.org)

The KISS principle (“Keep It Simple, Stupid”) has been applied effectively in many disciplines, including “software development, animation, photography, engineering, and strategic planning” (Wikipedia). In clinical medicine, perhaps the most elegant example of the KISS principle involves simple laboratory tests such as hemoglobin, creatinine, etc., that may be applied to diagnosis, prognosis, management, and documentation of outcomes of diseases.

The discovery of rheumatoid factor (RF)1 and antinuclear antibodies (ANA)2 in 1949 raised hope that similar, simple biomarkers could be applied to diagnosis, prognosis, and management of inflammatory rheumatic diseases. Laboratory biomarkers provide an invaluable foundation to understand pathogenesis and develop new therapies, such as biological agents, and are informative in groups of patients.

Nonetheless, laboratory tests have many limitations in the care of individual patients with rheumatic diseases. For example, in patients with rheumatoid arthritis (RA), RF is positive in only 69%3, anti-cyclic citrullinated peptide (anti-CCP) antibodies are positive in only 67%3, and erythrocyte sedimentation rate (ESR) is greater than 28 mm/h in only 60%4. Only about 1 in 50–100 people with a positive ANA has systemic lupus erythematosus (SLE)5. Indeed, no laboratory test (or any other single measure) can serve as a “gold standard” test for diagnosis and monitoring of all individuals with any rheumatic disease5.

Recognition of the limitations of laboratory tests in rheumatology patient care has led to development of pooled indices, such as the RA Core Data Set, Disease Activity Score (DAS), and Clinical Disease Activity Index (CDAI); the SLE Disease Activity Index (SLEDAI); Bath Ankylosing Spondylitis Disease Activity Index (BASDAI); Birmingham Vasculitis Activity Score; Western Ontario and McMaster University Osteoarthritis scale; Fibromyalgia Impact Questionnaire; and others (see Pincus and Sokka6). Each index includes quantitative patient self-report data to depict patient status.

These indices are widely used in clinical trials and other clinical research. However, they are generally too complex for usual care. Indeed, most rheumatology care is conducted without quantitative measures to inform clinical decisions and document the value of patient status, other than laboratory tests, the limitations of which formed the original basis for development of the clinical indices!

This situation suggests a return to the KISS principle to quantitate patient status, but with a significant departure from the traditional simple measures — patient self-report measures rather than (or in addition to) laboratory tests. Information from patients generally provides the foundation for most rheumatology clinical decisions regarding diagnosis and treatment, and is included in most indices. Why not regard patient measures, rather than laboratory tests, as the most valuable simple quantitative measures to assess and document care?

Of course, it is possible to oversimplify, such as the traditional 1–4 scales for functional class and radiographic score15. These are robust measures, but insensitive to change. By contrast, 0–10 scales for the 3 self-report measures in the RA Core Data Set, i.e., physical function, pain, and patient estimate of global status, distinguish between active and control treatments in RA clinical trials as efficiently as the other 4 Core Data Set measures, i.e., swollen joint count, tender joint count, physician global estimate, or acute-phase reactant (ESR or C-reactive protein)7. The Health Assessment Questionnaire (HAQ) or multidimensional HAQ (MDHAQ) physical function score, not a laboratory test or radiograph, is the most significant predictor of severe outcomes of RA, such as work disability or premature mortality5, in 17 of 18 studies that have included all 3 types of measures. Pain is the primary reason that patients seek rheumatology care. Patient global estimate is the most representative measure of status.

Application of the KISS principle has led to a simple
index known as the Routine Assessment of Patient Index Data 3 (RAPID3), scored 0–30, based on the three 0–10 scores for physical function, pain, and patient global estimate. RAPID3 is correlated with DAS28 and CDAI in clinical trials and clinical care, and also distinguishes active from control treatments as effectively as DAS28 and CDAI. RAPID3 is scored in less than 10 seconds on a one-page multidimensional HAQ, with scoring templates, 21-circle visual analog scales, and boxes to enter the data. By contrast, scoring requires 42 seconds for a traditional HAQ, 94 seconds for a formal joint count, 106 seconds for a CDAI, and 114 seconds for a DAS28.

Patient flow is not disrupted at all if the MDHAQ is distributed to all patients by a receptionist in the infrastructure of care, rather than in the examination room, after the visit, or selectively to certain patients. The MDHAQ provides a review of systems and recent medical history information for the physician to help manage patient care, which can save several minutes per patient. The treating physician should have the data for review with patients with all rheumatic diseases, ideally using a flow-sheet, to inform clinical decisions in patients. Further application of the KISS principle is seen in newer software systems such as GoTreatIT (DiaGraphIT AS, Kristiansand, Norway; www.diagraphit.com), a Norwegian software management system, for efficient data recording and management.

Patient questionnaires were initially regarded as surrogates for more “objective” measures such as laboratory tests and radiographs. However, patient self-report Core Data Set measures appear to be as reliable (reproducible) as joint count measures obtained by a physician. Their effectiveness in clinical trials, prognosis, and documentation compared to traditional joint count and radiographic and laboratory data is extensively recognized.

An MDHAQ-RAPID3 score is useful in all rheumatic diseases, including SLE, ankylosing spondylitis, vasculitis, psoriatic arthritis, gout, osteoarthritis, fibromyalgia, and Behçet’s disease. Of course, indices such as a SLEDAI, BASDAI, or other specialized index are more comprehensive, and will always be valuable in clinical research. Formal studies to compare the feasible RAPID3 to SLEDAI, BASDAI, and other indices would be of value, as feasibility is a stated aim of the outcome measures in RA clinical trials (OMERACT) program.

Patient scores for physical function, pain and global estimate, and RAPID3 may be regarded as “vital signs” in chronic rheumatic diseases, according to the KISS principle. Clinical decisions are based primarily upon information from a patient. RAPID3 can quantify that information to provide numbers rather than impressions for comparison from one visit to the next, with minimal cost and professional time. MDHAQ-RAPID3 might be included at all visits of all patients in the infrastructure of rheumatology care.

THEODORE PINCUS, MD.
New York University Hospital for Joint Diseases, New York, New York, USA;
TUULIKKI SOKKA, MD.
Jyväskylä Central Hospital, Jyväskylä, and Medcare Oy, Äänekoski, Finland

Address reprint requests to Dr. T. Pincus, NYU Hospital for Joint Diseases, 301 East 17th Street, New York, NY 10003. E-mail: tedpincus@gmail.com

REFERENCES
6. Pincus T, Sokka T. Can a Multi-Dimensional Health Assessment Questionnaire (MDHAQ) and Routine Assessment of Patient Index Data (RAPID) scores be informative in patients with all rheumatic diseases? Best Pract Res Cl Rheumatol 2007;21:733-53.
7. Pincus T, Amara I, Segurodo OG, Bergman M, Koch GG. Relative efficiencies of physician/assessor global estimates and patient questionnaire measures are similar to or greater than joint counts to distinguish adalimumab from control treatments in rheumatoid arthritis clinical trials. J Rheumatol 2008;35:201-5.